ARTICLE | Clinical News
Custirsen sodium: Phase III ongoing
July 20, 2015 7:00 AM UTC
OncoGenex said an IDMC recommended continuation of the open-label, international Phase III ENSPIRIT trial comparing weekly 640 mg IV custirsen plus IV Taxotere docetaxel given on day 1 of a 21-day cy...